Drug Trial Radar · NCT07891169
Master Protocol for Basket Clinical Trials of Targeted Therapies Based on Proteome and Whole Exome Sequencing Screening in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
2,800
Planned (sponsor's estimate)
Start
Nov 18, 2024
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- National Cancer Center, KoreaGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- First posted
- Oct 23, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Screening
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study Overview This study evaluates a proteogenomic screening platform to identify precise therapeutic targets for patients with advanced solid tumors. While traditional precision medicine relies on DNA sequencing (genomics), this research adds protein analysis (proteomics) to better understand how cancer cells function and respond to treatment. 1. Background and Purpose Standard genomic testing often fails to predict whether a patient will respond to a specific drug because DNA mutations do not always result in active protein expression. By integrating Whole Exome Sequencing (WES) with phosphoproteomics (the study of protein activation), this study aims to: * Identify active signaling networks that DNA testing alone might miss. * Evaluate the feasibility and cost-effectiveness of this integrated platform compared to traditional methods. * Help match patients to the most effective targeted therapies through a "Basket Trial" framework, where treatment is based on molecular signatures rather than where the cancer started in the body. 2. Target Population * Adults (19 years and older) with histologically confirmed metastatic or locally advanced solid tumors. * Patients with Stage III, IV, or those at a high risk of recurrence. * Participants must have a life expectancy of at least 3 months and a good performance status (ECOG 0-2). 3. Study Procedures * Specimen Collection: Researchers will collect tumor tissue through biopsy or surgery. To preserve the integrity of proteins, these samples must be snap-frozen (Fresh-Frozen) immediately after extraction. * Analysis: The study will analyze the tissue and blood samples to characterize the patient's unique proteogenomic profile. * Treatment Assignment: If a specific molecular variant is identified (such as HRD or ALK/ROS1/MET signatures), and a matching sub-protocol is available, the patient may be enrolled in a targeted therapy trial. Patients who do not meet these criteria will continue with the standard of care. 4. Expectations and Logistics This is a multicenter, prospective screening study involving a nationwide logistics system to ensure high-quality sample transport. The study aims to enroll a total of 2,800 subjects (approximately 560 per year) and is expected to continue through December 31, 2028. 5. Potential Benefits and Risks * Benefits: Participants may gain access to targeted therapies based on their cancer's specific molecular profile. * Risks: While the study does not add new invasive procedures beyond standard care, there are potential psychosocial risks related to genomic findings and the sharing of de-identified data for research purposes.
Conditions
- Advanced Solid Tumors
- Metastatic Solid Tumors
- Locally Advanced Solid Tumors
- Recurrent Solid Tumors
- Proteogenomic Screening and Molecular Signaling
- Basket Clinical Trial Framework
- Targeted Therapy Based on HRD (Homologous Recombination Deficiency) and ALK/ROS1/MET Signatures
Interventions
Homologous Recombination Deficiency (HRD)Drug
This arm consists of subjects identified with Homologous Recombination Deficiency (HRD)-positive proteogenomic signatures through the master screening protocol . These subjects are eligible for matching targeted therapy sub-protocols
ALK/ROS1/METDrug
ALK/ROS1/MET-targeted therapy (Crizotinib 250mg )
standard care treatmentDrug
This arm is for subjects who do not meet the specific molecular criteria for the available targeted sub-protocols following proteogenomic screening . These subjects will continue to receive the standard-of-care treatment at their respective institutions
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of Successful Identification of Actionable Therapeutic TargetsTime frame: From the date of pre-treatment tissue sample collection until the completion of proteogenomic analysis and report generation, assessed up to 3 weeks (21 days) per participant.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
National Cancer Center, Korea
Goyang, Gyeonggido, South Korea
National Cancer Center, Korea
Goyang-si, Gyeonggido, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.